Formulated for breast cancer to manage estrogen levels and support tumor growth inhibition.
Mechanism of Action
Aromasin is an irreversible, steroidal aromatase inactivator. It binds to the active site of the enzyme and causes permanent inactivation, preventing the conversion of androgens to estrogens in postmenopausal women.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
24 hours (half-life)
Contraindications
Premenopausal status, Pregnancy, Hypersensitivity to exemestane
Severe Adverse Events
Osteoporosis, Ischemic heart disease, Anaphylaxis — requires immediate medical attention
Common Side Effects
Hot flashes, Fatigue, Arthralgia
Uncommon Side Effects
Nausea, Insomnia, Headache
Drug Interactions
Alcohol, Rifampin, Phenytoin, St. John's Wort, Estrogen-containing therapies
Pregnancy Safety Warnings
FDA Category X: Strictly contraindicated in pregnancy. Breastfeeding: Not recommended.
Information related to Aromasin is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
